Clean Science and Technology Ltd reported a 26% year-over-year sales growth, with a steady revenue mix of 30% domestic and 70% international sales; EBITDA was INR 95 crores with margins at 42%. The company is on track to launch a pharma intermediate in Q3 and has incurred a capex of INR 155 crores in H1 FY 25.